The treatment effects and associated prognosis of combination therapies comprising PD-1/PD-L1 inhibitors and radiotherapy and/or chemotherapy in patients with ESCC need to be assessed in further studies. This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.